(Q38035035)

27 August 2017

title

Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes (English)

1 reference

27 August 2017

0 references

Kazutaka Saito

1

1 reference

27 August 2017

Kazunori Kihara

series ordinal

2

1 reference

27 August 2017

publication date

16 August 2012

1 reference

International Journal of Urology

27 August 2017

published in

1 reference

27 August 2017

volume

20

1 reference

27 August 2017

issue

2

1 reference

27 August 2017

page(s)

161-171

1 reference

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Immunity, Inflammation, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Cancer-related inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Interleukin-6 and renal cell cancer: production, regulation, and growth effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Role of systemic inflammatory response in predicting survival in patients with primary operable cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Phase-II trial of combination treatment of interferon-α, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

An integrated view of humoral innate immunity: pentraxins as a paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Innate immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Human C-reactive protein: expression, structure, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Transcription factor c-Rel enhances C-reactive protein expression by facilitating the binding of C/EBPβ to the promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

C-reactive protein: risk marker or mediator in atherothrombosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

The phenomenon of the acute phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

What does minor elevation of C-reactive protein signify?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Plasma C-reactive protein and risk of cancer: a prospective study from Greece.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Role of C-reactive protein as a biomarker for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Metastatic renal carcinoma comprehensive prognostic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Pretreatment serum CRP and response to interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Immunotherapy for advanced renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Grading systems in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

High-sensitivity C-reactive protein and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Cardiovascular morbidity in long-term survivors of metastatic testicular cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Increased mortality rates in young and middle-aged patients with malignant germ cell tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

C-reactive protein; a potential marker of second cancer and cardiovascular disease in testicular cancer survivors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03121.X

10.1111/J.1442-2042.2012.03121.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference